Comparison of survivor scores for differentiation therapy of cancer to those for checkpoint inhibition: Half full or half empty
出版年份 2019 全文链接
标题
Comparison of survivor scores for differentiation therapy of cancer to those for checkpoint inhibition: Half full or half empty
作者
关键词
-
出版物
TUMOR BIOLOGY
Volume 41, Issue 9, Pages 101042831987374
出版商
SAGE Publications
发表日期
2019-09-09
DOI
10.1177/1010428319873749
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors
- (2018) Kristian M. Hargadon et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- MUC1-C drives myeloid leukaemogenesis and resistance to treatment by a survivin-mediated mechanism
- (2018) Dina Stroopinsky et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
- (2018) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer
- (2018) Nicholas Borcherding et al. JOURNAL OF MOLECULAR BIOLOGY
- The Dualistic Origin of Human Tumors
- (2018) Jinsong Liu SEMINARS IN CANCER BIOLOGY
- NKG2D and Its Ligands: “One for All, All for One”
- (2018) Alessandra Zingoni et al. Frontiers in Immunology
- Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC).
- (2018) Luis G. Paz-Ares et al. JOURNAL OF CLINICAL ONCOLOGY
- 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer
- (2018) Hossein Borghaei et al. Journal of Thoracic Oncology
- Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy
- (2018) Yiyi Yan et al. Frontiers in Immunology
- NKG2D Ligands–Critical Targets for Cancer Immune Escape and Therapy
- (2018) Dominik Schmiedel et al. Frontiers in Immunology
- Immunotherapy 2.0: Improving the Response to Checkpoint Inhibitors
- (2018) M.J. Friedrich JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
- (2017) David P. Carbone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
- (2017) Richard M. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
- (2017) Hashem O. Alsaab et al. Frontiers in Pharmacology
- Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities
- (2016) KM Morrissey et al. CTS-Clinical and Translational Science
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- (2016) J.M. Michot et al. EUROPEAN JOURNAL OF CANCER
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
- (2016) Corey J Langer et al. LANCET ONCOLOGY
- Cocktails for cancer with a measure of immunotherapy
- (2016) Heidi Ledford NATURE
- PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
- (2016) Paul T. Nghiem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab for Patients with Relapse after Allogeneic Transplantation
- (2016) Matthew S. Davids et al. NEW ENGLAND JOURNAL OF MEDICINE
- Regulatory Role of IL-1R8 in Immunity and Disease
- (2016) Martina Molgora et al. Frontiers in Immunology
- Neuroblastoma
- (2016) Katherine K. Matthay et al. Nature Reviews Disease Primers
- Acute myeloid leukemia-Major progress over four decades and glimpses into the future
- (2015) Hagop Kantarjian AMERICAN JOURNAL OF HEMATOLOGY
- Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States
- (2015) Martin Tallman et al. Clinical Lymphoma Myeloma & Leukemia
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- EZH2 as a potential target in cancer therapy
- (2014) Michael T McCabe et al. Epigenomics
- The CD40/CD40L system: A new therapeutic target for disease
- (2013) Bikui Zhang et al. IMMUNOLOGY LETTERS
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia
- (2011) Y. Shen et al. BLOOD
- Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor
- (2011) M. S. Redell et al. BLOOD
- The PD-1 pathway in tolerance and autoimmunity
- (2010) Loise M. Francisco et al. IMMUNOLOGICAL REVIEWS
- A practical guide to understanding Kaplan-Meier curves
- (2010) Jason T. Rich et al. OTOLARYNGOLOGY-HEAD AND NECK SURGERY
- Molecular mechanism and function of CD40/CD40L engagement in the immune system
- (2009) Raul Elgueta et al. IMMUNOLOGICAL REVIEWS
- Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group Study
- (2009) Katherine K. Matthay et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started